Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.

Neumora Therapeutics, Inc. Common Stock

Brain diseases collectively represent one of the largest areas of unmet medical need, affecting upwards of 1.5 billion patients globally. Neumora was founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. Our goal is to redefine neuroscience drug development by bringing forward the next generation of novel therapies that offer improved treatment outcomes and quality of life for patients.

We’ve built a pipeline comprised of programs for neuropsychiatric disorders and neurodegenerative diseases, each targeting a novel mechanism of action where we can leverage our precision neuroscience approach. Our pipeline currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. 

Neumora is committed to addressing some of the most prevalent brain health disorders and transforming the standard of care for millions of patients living with brain diseases. Learn more about Neumora and career opportunities on our website below.

Mubadala Capital Ventures

Invus

Abu Dhabi Growth Fund

Altitude Life Science Ventures

Amgen

EXOR N.V.

ARCH Venture Partners

Newpath Management

Polaris Partners

F-Prime Capital

Neumora

We are delighted to welcome Kaya Pai Panandiker as Chief Commercial Officer. Kaya brings to Neumora extensive commercial strategy and execution expertise, having led the launches of multiple neuropsychiatry products throughout her career. Read more: https://lnkd.in/ex-Zr2JP

Each year, our CEO Excellence Awards celebrate individuals or cross functional teams who demonstrate our values every day by achieving the extraordinary, creating value and doing what is right. We were thrilled to recognize our 2023 winners, Karla Zeitz, Jason Morton, Partha Mudipalli, Ph.D., Hong Ji, Santnu P., Michael Eyre, Heather Stemper, Palwasha T., Leanna Bui, Tash Barrow, Kelly Voong and Anh Le Vynh, for their outstanding contributions to Neumora. Thank you for your unwavering dedication to this work!

We’ve had a great week connecting with #JPM24 attendees! #ICYMI, check out CEO Henry Gosebruch’s podium presentation, outlining the exciting year ahead and our industry-leading pipeline. We look forward to continuing to pioneer a new era in brain disease and lead innovation in brain health throughout 2024. https://lnkd.in/eRFzBnEY

Neumora was founded to improve the lives of people living with brain diseases. To do that, we’ve built an industry-leading pipeline comprised of programs for neuropsychiatric disorders and neurodegenerative diseases, each targeting a novel mechanism of action. Learn more about our pipeline below. #JPM24

We are heading to San Francisco next week for #JPM24! CEO Henry Gosebruch will present on Monday, January 8 at 11:15AM PT. Learn more below. https://lnkd.in/ePiU73Zx

We are headed into this holiday season filled with gratitude for those around us. Wishing you the happiest of holidays from all of us at Neumora!

A recent NAMI study found that 64% of people with a mental illness said holidays make their conditions worse. It's important to put yourself first and prioritize your well-being, especially during the holiday season. We're sharing some of our favorite tips from NAMI and The Jed Foundation (JED) on how to reduce stress and maintain good #mentalhealth in the coming weeks. In an emergency, dial 988 to reach the suicide and crisis lifeline.

We are pleased to welcome Jason G. Duncan to Neumora as Chief Legal Officer. Jason's decades of legal, compliance, development and operations experience will be invaluable to our team as we continue to progress our pipeline. Read more: https://lnkd.in/eUdk_Gkr

We had a great time in Tampa at #ACNP2023, where Dr. Sanjay Mathew presented data from our #MDD program. It was great to connect with so many neuropsych thought leaders!

Today we announced IND clearance and the initiation of a Phase 1 study for NMRA-266, our M4 positive allosteric modulator. Read more here. https://lnkd.in/e_Vz_cjb

	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
average inventory
average payables		1.20M -	2.02M 68.35%	4.39M 117.64%	3.74M 14.82%
average receivables		74K -	174K 135.14%	559.50K 221.55%	929K 66.04%
book value per share		-0.62 -	-2.14 244.57%	-2.94 37.40%
capex per share		-0.01 -	-0.01 37.15%	-0.00 37.45%
capex to depreciation		-12.38 -	-1.52 87.73%	-0.86 43.35%	-0.18 79.64%
capex to operating cash flow		0.05 -	0.01 77.70%	0.00 58.94%	0.00 83.89%
capex to revenue
cash per share		1.26 -	2.69 113.18%	2.45 9.13%
days of inventory on hand
days payables outstanding
days sales outstanding
debt to assets		0.01 -	0.00 53.73%	0.02 314.36%	0.01 46.77%
debt to equity		-0.02 -	-0.01 70.88%	-0.02 199.42%	0.01 159.03%
dividend yield
earnings yield		-65.33K -	-156.18K 139.05%	-86.15K 44.84%
enterprise value		-189.93M -	-407.19M 114.39%	-232.50M 42.90%	-368.81M 58.63%
enterprise value over ebitda		1.99 -	1.72 13.61%	1.72 0.06%
ev to operating cash flow		7.10 -	5.40 23.93%	2.02 62.52%	2.26 11.62%
ev to sales
free cash flow per share		-0.18 -	-0.50 171.69%	-0.76 51.38%
free cash flow yield		-18.47K -	-50.17K 171.69%	-75.95K 51.38%
graham net net		-0.66 -	-2.27 244.29%	-3.29 45.02%
graham number		3.02 -	8.67 187.00%	7.55 12.94%
income quality		0.27 -	0.32 17.90%	0.88 176.18%	0.69 21.15%
intangibles to total assets	0 -	0	0	0	0
interest coverage
interest debt per share		0.01 -	0.01 0.34%	0.06 311.40%
inventory turnover
invested capital		-0.02 -	-0.01 70.88%	-0.02 199.42%	0.01 159.03%
market cap		1.52K -	1.52K 0%	1.52K 0%
net current asset value	-21K -	-98.49M 468,895.24%	-338.92M 244.11%	-485.13M 43.14%	451.16M 193.00%
net debt to ebitda		1.99 -	1.72 13.61%	1.72 0.06%
net income per share		-0.65 -	-1.56 139.05%	-0.86 44.84%
operating cash flow per share		-0.18 -	-0.50 181.84%	-0.76 52.34%
payables turnover
receivables turnover
research and ddevelopement to revenue
return on tangible assets		-0.50 -	-0.55 10.23%	-0.31 44.44%
revenue per share
roe		1.05 -	0.73 30.62%	0.29 59.85%
roic		1.06 -	0.74 30.14%	0.30 58.73%
sales general and administrative to revenue
shareholders equity per share		-0.62 -	-2.14 244.57%	-2.94 37.40%
stock based compensation to revenue
tangible asset value	-21K -	-94.38M 449,347.62%	-325.22M 244.57%	-446.85M 37.40%	469.08M 204.97%
tangible book value per share		-0.62 -	-2.14 244.57%	-2.94 37.40%
working capital	-21K -	184.47M 878,533.33%	392.32M 112.68%	364.26M 7.15%	453.17M 24.41%

COM:NEUMORATX

Neumora Therapeutics, Inc.

Last Close

9.69

22/11 21:00

Market Cap

1.72B

Beta: -

Volume Today

490.17K

Avg: -

Preview